Oryzon Genomics
Update in progressORY.MC (MCE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company developing epigenetics-based therapies for cancer, CNS disorders, and hematology. Lead programs include iadademstat (ORY-1001), a selective LSD1 inhibitor in Phase II for oncology, and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor in Phase II for CNS and psychiatric diseases. Other candidates are ORY-3001 (LSD1, preclinical) and ORY-4001 (HDAC-6 inhibitor for neurological disorders). Based in Cornellà de Llobregat, Spain, it collaborates with Columbia University and INGM Madrid and conducts CRADA-driven trials.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.25
- Governance
- 0.17
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketMCE (MCE)
- LocationSpain
- CEODr. Carlos Manuel Buesa Arjol
- Founded2000
- Employees46
- Websitewww.oryzon.com/en
Identifiers
- ISINES0167733015
- LEI95980063R15RDF29DK13